MagnetOs Granules vs. Autograft in Instrumented Posterolateral Spinal Fusion

  • End date
    Jul 14, 2022
  • participants needed
  • sponsor
    M.C. Kruyt, MD, PhD
Updated on 14 May 2021
back pain
bone graft


The purpose of this study is to demonstrate non-inferiority of MagnetOs Granules as an alternative to autologous bone graft in adult patients undergoing an instrumented posterolateral fusion of the thoracolumbar, lumbar or lumbosacral spine, in terms of efficacy and safety. After instrumentation and based on randomization, one side of the spine will be grafted with MagnetOs Granules and the other side with autologous bone graft. Thereby, each patient serves as its own control.


Posterolateral spinal fusion is currently performed by using large amounts of autologous bone graft. Drawbacks of bone grafting include the need for an additional surgical procedure, limited supply, sub-optimal bone quality in osteoporotic patients and harvesting morbidity, which led to the development of numerous bone graft substitutes. Recently, a promising synthetic graft substitute has been developed that has shown favorable results in pre-clinical studies. This product, MagnetOs Granules, is CE-marked and received 510(k) clearance from the US Food and Drug Administration. The aim of the current study is to demonstrate non-inferiority of MagnetOs Granules compared to autograft in instrumented posterolateral spinal fusion, in terms of efficacy and safety.

This study is designed as a multicenter, observer blinded, randomized, controlled non-inferiority trial with intra-patient comparisons. A total of 100 adult patients qualified for posterolateral spinal fusion in the thoracolumbar and lumbosacral region (T10-S2) will be recruited and enrolled. According to a randomization scheme, one side of the spine will be grafted with the MagnetOs Granules and the other side with bone harvested from the iliac crest and local bone. The rest of the surgical procedure will be according to standard care.

The primary efficacy outcome is the rate of successful posterolateral spinal fusion after one year, assessed on CT-scans. Non-inferiority of the MagnetOs condition compared to the autograft condition will be assessed using a McNemar's test. The primary safety outcome is the number and nature of (serious) adverse events related to the surgical procedure compared to control populations from literature. Secondary outcomes are the comparison to its predicate (AttraX Putty), relation between posterolateral fusion and interbody fusion after one-year, posterolateral spinal fusion rate after two years, relevance of iliac crest donor site pain and the incidence of long-term complication and relation with risk factors in the combined population of this study and a recently completed clinical trial.

Condition Spinal Fusion, spinal fusions
Treatment Instrumented posterolateral spinal fusion, MagnetOs™ Granules, Autologous bone graft
Clinical Study IdentifierNCT03625544
SponsorM.C. Kruyt, MD, PhD
Last Modified on14 May 2021


Yes No Not Sure

Inclusion Criteria

To be treated with instrumented posterolateral thoracolumbar spinal fusion with the use of iliac crest bone, with or without additional posteriorly inserted interbody devices (PLIF, TLIF), because of (1) deformity, (2) structural instability and/or (3) expected instability as a result of decompression for spinal stenosis
Deformity is defined as a scoliosis in the coronal plane of >20 and/or a sagittal balance disturbance according the SRS/Schwab classification on standardized standing full spine radiographs
Preoperative instability is defined as a progressive angular deformity or spondylolisthesis in standing radiographs
Decompression for spinal stenosis is done in the occurrence of radiological evidence of stenosis on MRI and clinical leg and/or back pain with one or more of the following phenomena: radiculopathy, sensory deficit, motor weakness, reflex pathology or neurogenic claudication
Non-responsive to at least 6 months of non-operative treatment prior to study enrollment
Fusion indicated for one to six levels in the T10 to S2 region. In case of vertebral osteotomies (PSO or VCR) the osteotomized segment will not be included in the assessment of the fusion rate
Willing and able to understand and sign the study specific Patient Informed Consent
Skeletally mature between 18 and 80 years of age

Exclusion Criteria

Any previous surgical attempt(s) for spinal fusion (revision surgery) of the intended segment(s)
Previous treatments that compromise fusion surgery like irradiation
Previous autologous bone grafting procedures that compromise the quality and amount of iliac crest bone grafting
Indication for spinal fusion because of an acute traumatic reason, like a spinal fracture
Active spinal and/or systemic infection
Spinal metastasis in the area intended for fusion
Systemic disease or condition, which would affect the subjects ability to participate in the study requirements or the ability to evaluate the efficacy of the graft (e.g. active malignancy, neuropathy, pregnancy)
At risk to be non-compliant e.g.: (recently treated for) substance abuse, detainee, likely to immigrate
Participation in clinical trials evaluating investigational devices, pharmaceuticals or biologics within 3 months of enrollment in this study
Female patients who intend to be pregnant within 1.5 year of enrollment in the study
Body mass index (BMI) larger than 36 (morbidly obese)
Being expected to require additional surgery to the same spinal region within the next 6 months
Current or recent (<1yr) corticosteroid use equivalent to prednisone 5mg/day, prescribed for more than 6 weeks
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note